Stockreport

Zai Lab Initiates Global Phase 2 Clinical Trial Evaluating ZL-1102 As a Topical Treatment for Chronic Plaque Psoriasis

Zai Lab Limited - American Depositary Shares  (ZLAB) 
US:NASDAQ Investor Relations: zailaboratory.com/about/investors.php
PDF This is the first compound in Zai’s portfolio of internally developed drugs to advance into Phase 2, demonstrating Zai’s global capabilitiesBased on a proof-of-concept s [Read more]